HB1325 creates a Colorado ibogaine research pilot program within the Behavioral Health Administration (BHA) to study the safety and effectiveness of ibogaine for treating mental health conditions and substance use disorders. The bill authorizes the BHA to approve up to five pilot sites, help them pursue federal authorization and FDA investigational new drug approvals, coordinate with federal agencies, contract with experts, seek grants, and award pilot-site grants. It also requires rules governing site selection, data collection, adverse-event reporting, and program administration, and it establishes a dedicated cash fund to receive gifts, grants, donations, and appropriations for the pilot.
The bill also amends Colorado’s natural medicine laws to incorporate ibogaine and certain semi-synthetic ibogaine products into the state’s regulated natural medicine framework, subject to board approval, director approval, and state licensing authority permissions. It adds or revises rules for administration sessions, facilitator oversight, medical screening, monitoring, aftercare, licensing, testing, temporary premises, and a new limited regulated natural medicine sales license that can be co-located with a healing center. The bill further expands licensing and enforcement provisions, including cease-and-desist authority for unlicensed activity and updated definitions and protections for natural medicine businesses and participants.
In addition to the pilot program, the bill creates liability protections for physicians, health-care professionals, facilitators, and pilot sites when they act within the law and without intentional misconduct, gross negligence, or deviation from accepted standards of practice. It also includes a benefit-sharing requirement for ibogaine-related activity, directing applicants and licensees to consult with Indigenous communities traditionally connected to ibogaine or iboga and to document plans that share research or commercialization benefits, while explicitly stating that Indigenous communities are not required to disclose traditional knowledge or ceremonial practices.
The bill’s impact on state law is substantial: it adds a new research program, creates a new funding mechanism, expands the regulated natural medicine code, and gives the state licensing authority and BHA new rulemaking, oversight, and enforcement responsibilities. It also changes how healing centers may operate, including temporary premises and limited sales licenses, and it prioritizes applicants who participated in the ibogaine pilot when later licensing opportunities become available. The pilot and several related provisions are contingent on federal approval and, for the pilot program, on sufficient private or public funding.
Overall, the sentiment reflected in committee and floor votes appears broadly supportive, with strong majorities advancing the bill through both chambers and unanimous or near-unanimous votes on several amendments. The main points of contention appear to be the use of ibogaine, a Schedule I substance, the need for federal approval and funding before implementation, and the scope of commercialization and licensing changes. The bill also reflects sensitivity around Indigenous benefit-sharing and ethical sourcing, suggesting those issues were important in shaping the final version.
HB1325 would amend Colorado’s natural medicine statutes to add ibogaine and semi-synthetic ibogaine pathways to the state’s regulatory framework, create an ibogaine research pilot program in the Behavioral Health Administration, and establish a dedicated cash fund for pilot administration and grants. It also expands rulemaking, licensing, testing, enforcement, and liability provisions under the natural medicine code, including new temporary premises and limited sales license structures, while making implementation of the pilot contingent on federal approval and sufficient funding.
The bill appears to have had generally favorable support in both chambers, as shown by strong committee and floor votes and the adoption of multiple amendments without opposition or with only limited dissent. The discussion context suggests lawmakers were receptive to the bill’s public-health and research framing, especially its focus on mental health, substance use disorder treatment, and veterans, while still imposing safeguards, funding conditions, and federal-compliance requirements.
The most notable areas of contention are the use of ibogaine itself, given its status as a Schedule I controlled substance and the need for federal authorization before the pilot can operate, and the extent to which Colorado should move toward regulated therapeutic use versus research-only access. Additional concerns center on patient safety, medical oversight, testing standards, liability protections, and the bill’s benefit-sharing requirements tied to Indigenous communities and sourcing practices. The bill also depends on private or public donations to trigger and sustain the pilot, which may have raised practical concerns about feasibility and implementation.